Search - tctmd.com

Displaying 1 - 20 of 347

Sort: Relevancy | Date

News Opinion Editor's Corner TCT 2016

My Takeaways From TCT 2016: Surprises, Presuppositions, and the Gift of the Giveaway

Shelley Wood

November 07, 2016

News Conference News TCT 2016

No Scares From SCAAR: Stent Thrombosis Rates in Newest DES Are Similar—and Low

Shelley Wood

November 07, 2016

News Conference News TCT 2016

TCT Mock Election: And the Winner Is...

Shelley Wood

November 02, 2016

News Conference News TCT 2016

Debate Over Low-Risk TAVR Hinges on Definition of Patient Population and Shared Decision-Making

Yael L. Maxwell

November 02, 2016

News Conference News TCT 2016

Transfemoral—but Not Transthoracic—TAVR Has Early Quality-of-Life Advantage Over Surgery in Intermediate-Risk Patients

Todd Neale

November 02, 2016

News Conference News TCT 2016

COLOR: PCI of Lipid-Rich Plaque Not Associated With Increased Risk of Adverse Events

Michael O'Riordan

November 01, 2016

Presentation TCT 2016

Is Ablation an Alternative to Triple Therapy in Patients With Atrial Fibrillation and PCI or ACS?

Presenter: Martin W. Bergmann, Samir R. Kapadia, Vivek Y. Reddy

November 01, 2016

Presentation TCT 2016

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

Presenter: Martin W. Bergmann, Samir R. Kapadia, Harvey D. White

November 01, 2016

Presentation TCT 2016

Surveying the Global Landscape of TAVR Newcomers

Presenter: Ganesh Manoharan, Hendrik Treede, Martin B. Leon

November 01, 2016

Presentation TCT 2016

Selecting the Right LAA Closure Device Based on Patient Characteristics and LAA Anatomy: Occluder, Ligation, or Clipping

Presenter: Martin W. Bergmann, Samir R. Kapadia, Jason H. Rogers

November 01, 2016

Presentation TCT 2016

Xeltis: Design and Clinical Updates

Presenter: Ganesh Manoharan, Hendrik Treede, Christian M. Spaulding

November 01, 2016

Presentation TCT 2016

Centera: Design and Clinical Updates

Presenter: Ganesh Manoharan, Hendrik Treede, Stephen G. Worthley

November 01, 2016

Presentation TCT 2016

Is LAA Closure an Alternative to Triple Therapy for all Patients or Those at High Bleeding Risk? Current Dataset

Presenter: Martin W. Bergmann, Samir R. Kapadia, Brian K. Whisenant

November 01, 2016

Presentation TCT 2016

Venus A Valve: Design and Clinical Updates

Presenter: Ganesh Manoharan, Hendrik Treede, Hasan Jilaihawi

November 01, 2016

Presentation TCT 2016

Why Triple Therapy? Rationale and Potential Role for LAA Closure in the PCI Patient

Presenter: Martin W. Bergmann, Samir R. Kapadia, Ashish Pershad

November 01, 2016

Presentation TCT 2016

Jena Valve: Design and Clinical Updates

Presenter: Ganesh Manoharan, Hendrik Treede

November 01, 2016

Presentation TCT 2016

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx, Deepak L. Bhatt

November 01, 2016

Presentation TCT 2016

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx, Roxana Mehran

November 01, 2016

Presentation TCT 2016

Which Device and Technique for This Patient?

Presenter: Ganesh Manoharan, Hendrik Treede, Tamim Nazif, Torsten P. Vahl

November 01, 2016

Presentation TCT 2016

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx

November 01, 2016

Advertisement

My Takeaways From TCT 2016: Surprises, Presuppositions, and the Gift of the Giveaway

No Scares From SCAAR: Stent Thrombosis Rates in Newest DES Are Similar—and Low

TCT Mock Election: And the Winner Is...

Debate Over Low-Risk TAVR Hinges on Definition of Patient Population and Shared Decision-Making

Transfemoral—but Not Transthoracic—TAVR Has Early Quality-of-Life Advantage Over Surgery in Intermediate-Risk Patients

COLOR: PCI of Lipid-Rich Plaque Not Associated With Increased Risk of Adverse Events

Is Ablation an Alternative to Triple Therapy in Patients With Atrial Fibrillation and PCI or ACS?

Should the New Oral Anticoagulants (vs Warfarin) Change the Equation of Triple Therapy vs LAA Closure?

Surveying the Global Landscape of TAVR Newcomers

Selecting the Right LAA Closure Device Based on Patient Characteristics and LAA Anatomy: Occluder, Ligation, or Clipping

Xeltis: Design and Clinical Updates

Centera: Design and Clinical Updates

Is LAA Closure an Alternative to Triple Therapy for all Patients or Those at High Bleeding Risk? Current Dataset

Venus A Valve: Design and Clinical Updates

Why Triple Therapy? Rationale and Potential Role for LAA Closure in the PCI Patient

Jena Valve: Design and Clinical Updates

The RE-DUAL PCI Trial: Dabigatran in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

The AUGUSTUS Trial: Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

Which Device and Technique for This Patient?

The ENTRUST AF-PCI Trial: Edoxaban in Patients With Atrial Fibrillation and PCI - Design, Rationale, and Status

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content